Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Blood (2023) 142 (Supplement 1): 6724.

https://doi.org/10.1182/blood-2023-186599

Published: 2023

Journal Articles

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Blood (2023) 142 (Supplement 1): 6742.

https://doi.org/10.1182/blood-2023-185792

Published: 2023

Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Blood (2023) 142 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2023-185699

Published: 2023

Journal Articles

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Blood (2022) 140 (Supplement 1): 4452–4453.

https://doi.org/10.1182/blood-2022-166870

Published: 2022

Journal Articles

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Blood (2022) 140 (Supplement 1): 4423–4425.

https://doi.org/10.1182/blood-2022-168742

Published: 2022

Journal Articles

Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study

Blood (2022) 140 (Supplement 1): 7219–7221.

https://doi.org/10.1182/blood-2022-165913

Published: 2022

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Blood (2021) 138 (25): 2686–2695.

https://doi.org/10.1182/blood.2021011285

Published: 2021

Includes: Supplemental data

Journal Articles

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal

Blood (2021) 138 (Supplement 1): 464.

https://doi.org/10.1182/blood-2021-146040

Published: 2021

Journal Articles

Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Magaret Macro, Cyrille Touzeau, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, Benjamin Hebraud, Olivier Decaux, Samantha Schulmann, Caroline Bureau Lenoir, Pascal Godmer, Jean-Jacques Parienti, Xavier Leleu

Blood (2021) 138 (Supplement 1): 83.

https://doi.org/10.1182/blood-2021-148152

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140713

Published: 2020

Journal Articles

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Blood (2019) 134 (Supplement_1): 1537.

https://doi.org/10.1182/blood-2019-127560

Published: 2019

Journal Articles

Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study

Blood (2016) 128 (22): 2777.

https://doi.org/10.1182/blood.V128.22.2777.2777

Published: 2016

Journal Articles

Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party

Blood (2016) 128 (22): 2266.

https://doi.org/10.1182/blood.V128.22.2266.2266

Published: 2016

Journal Articles

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Eileen Mary Boyle, MD MSc, Marie-Odile Petillon, MD, Charles Herbaux, MD, Johanna Mimouni, Xavier Leleu, Lionel Karlin, MD, Chantal Doyen, MD, Marc Wetterwald, MD PhD, Muriel Roussel, MD, Cyrille Hulin, Bruno Royer, MD, Margaret Macro, Philippe Moreau, Karel Fostier, MD, Mamoun Dib, Sabine Brechignac, MD, Caroline Bureau, Gerald Marit, MD, Adrian Tempescul, MD, Marie Lorraine Chretien, Charles Zarnitsky, Cecile Fohrer, MD, Aurore Perrot, MD, Lotfi Benboubker, MD PhD, Laurent Voillat, Jean Valere Malfuson, Clara Mariette, Mourad Tiab, Sophie Rigaudeau, Arnaud Jaccard, MD PhD, Anne-Marie Stoppa, Laure Vincent, Jean Claude Eisenmann, MD, Laurent Frenzel, Bertrand Arnulf, MD, Mohamad Mohty, MD PhD, Philippe Rodon, MD, Brigitte Kolb, Olivier Decaux, MD PhD, Pascal Godmer, David Beauvais, Benjamin Carpentier, Sarah Bonnet, MD, Thomas Longval, Mathieu Dewevre, Herve Avet-Loiseau, MD PhD, Michel Attal, Susanna Schraen, PharmD, Thierry Facon

Blood (2016) 128 (22): 2138.

https://doi.org/10.1182/blood.V128.22.2138.2138

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Xavier Cahu, MD, Patrice Chevallier, MD, PhD, Aline Clavert, MD, Felipe Suarez, MD, PhD, Mauricette Michallet, MD, Nathalie Fegueux, MD, Stephane Vigouroux, MD, Didier Blaise, Gérard Socié, MD, PhD, Clara Mariette, Karin Bilger, MD, Ibrahim Yakoub-Agha, MD, PhD, Regis Peffault de Latour, Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 3373.

https://doi.org/10.1182/blood.V122.21.3373.3373

Published: 2013

Journal Articles

Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study

Clara Mariette, Anne Thiebaut, Jean-Yves Cahn, MD, PhD, Didier Hocquet, Agnes Huynh, Françoise Isnard, MD, Faezeh Legrand, MD, Véronique Lhéritier, Emmanuelle Tavernier, MD, Emmanuel Raffoux, Norbert Ifrah, Aline Schmidt, Herve Dombret, MD, PhD

Blood (2013) 122 (21): 1394.

https://doi.org/10.1182/blood.V122.21.1394.1394

Published: 2013

Journal Articles

Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts)

Blood (2012) 120 (21): 890.

https://doi.org/10.1182/blood.V120.21.890.890

Published: 2012

Journal Articles

Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 Patients

Edouard Cornet, MD, Cécile Tomowiak, MD, Aline Tanguy-Schmidt, MD, Stéphane Leprêtre, MD, Jehan Dupuis, MD, Pierre Feugier, MD, PhD, Alain Devidas, MD, Clara Mariette, MD, Véronique Leblond, MD, PhD, Catherine Thieblemont, MD, PhD, Patricia Validire-Charpy, MD, Laurent Sutton, MD, Emmanuel Gyan, MD, PhD, Jean-Claude Eisenmann, MD, Xavier Troussard, MD

Blood (2012) 120 (21): 3921.

https://doi.org/10.1182/blood.V120.21.3921.3921

Published: 2012

NARROW

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study

Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study

Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts)

Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only